Lannett Delivers On Internal Pipeline With Mycophenolate Mofetil Launch
Points To Technical Barriers And Limited Competition On Roche’s CellCept
Executive Summary
Lannett has launched its internally-developed generic mycophenolate mofetil 200mg/ml oral suspension in the US, highlighting a first-cycle FDA approval as evidence of its capabilities as well as pointing to limited competition on the rival to Roche’s CellCept.